- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01639898
POEMS Syndrome Treatment With Lenalidomide (POEMS)
Phase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome.
POEMS syndrome is a rare form of B cell dyscrasia combining a proliferation usually of plasma cells, a polyneuropathy, osteocondensing bone lesions and multiple other clinical signs. Lenalidomide appears to be particularly efficient in this pathology.
The investigators propose a phase II multicentre protocol, based on the use of lenalidomide combined with dexamethasone in patients presenting a POEMS syndrome, either de novo or resistant or in relapse.
Patients who can be treated by local radiation or intensive treatment with stem cell support will undergo 2 cycles of the lenalidomide-dexamethasone (Len-Dex) combination before radiation or intensive treatment (Group 1), the other patients will undergo 9 cycles of the Len-Dex combination (Group 2).
A biological study is coupled with this clinical protocol in order to define the best biological markers predicting clinical responses, to better understand the POEMS pathophysiological mechanisms and to set up a bank of samples which can be used to study this rare pathology.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators propose to simultaneously set up two Phase II therapeutic trials: Trial "2 cycles" and trial "9 cycles" (Fleming plan in one stage).
This will mean prospective multicentre studies, around a treatment with the lenalidomide-dexamethasone combination in patients suffering from POEMS syndrome either de novo, resistant or in relapse.
Both trials carried out in parallel are complementary regarding the eligibility criteria:
- Group 1: the "2-cycles" trial will be available to patients who can be treated by radiation or intensive treatment (75 % of cases occurring in front line); they will then undergo 2 cycles of the lenalidomide-dexamethasone combination before radiation or intensive treatment (Group 1).
- Group 2 : the "9-cycles" trial will be available to all other front-line patients (25 % of front-line patients) or patients in relapse or resistant, they will undergo 9 cycles of the lenalidomide-dexamethasone combination followed by maintenance therapy with lenalidomide alone for one year (Group 2).
Both these trials carried out within the same study will enable us to answer the question of potential efficacy of lenalidomide in POEMS syndrome and could enable us to draw up a new therapeutic standard.
Main objective:
Group 1: to evaluate the efficacy of the Len-Dex combination on the biological response after 2 cycles in patients with POEMS syndrome who can undergo radiation or intensive treatment.
Group 2: to evaluate the efficacy of the Len-Dex combination on the biological response in patients with POEMS syndrome who cannot be treated by radiation or intensive treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Angers, France, 49933
- CHU d'Angers
-
Caen, France, 14000
- CHU de Caen
-
Lille, France, 59037
- CHU de Lille
-
Limoges, France, 87042
- CHU de Limoges
-
Lyon, France, 69373
- Centre Leon Berard
-
Lyon, France, 69000
- Hospices Civil de Lyon
-
Nantes, France, 44093
- CHU de Nantes
-
Paris, France, 75010
- Hôpital Saint-Louis
-
Paris, France, 75743
- Hôpital Necker
-
Paris, France, 75013
- Pitie Salpetriere
-
Toulouse, France, 31059
- CHU de Toulouse
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients suffering from POEMS syndrome (Mayo Clinic criteria)
- Patients with a localised disease who can be treated with radiation and those with a disseminated disease and who can be treated intensively will be included in Group 1, all other patients will be included in Group 2.
- Patients aged of 18 or more
- Patients who do not show uncontrolled thrombosis
- Patients who have been duly informed and who have signed a consent form.
- Patients must respect all the lenalidomide Pregnancy Prevention Program (PPP) requirements described in appendix of the protocol.
- Patients registered with the French National Health System.
Exclusion Criteria:
- Women who are pregnant, or suspected to be pregnant or breastfeeding
- Pathology not linked with POEMS, contraindicating one of the studied drugs
- Patients suffering from a deficiency which does not allow them full understanding of the trial requirements and which could compromise proper consent from the patient and/or observance of the protocol and continuous participation in the trial.
- Prior history of malignancy other than POEMS syndrome or active other cancer or other serious illness.
- Any contraindication to Revlimid® or to one of its excipient.
- Patient with clearance creatinine < 30mL/min.
- Hepatic insufficiency
- Patient with Absolute Neutrophil count (ANC) < 1,0 x 109/L
- Patient with platelet count < 75 x 109/L
- Use of any other experimental drug or therapy within 28 days of baseline
- Known hypersensitivity to thalidomide
- Instable, clinically significant ECG findings
- Known positive for HIV, or active infectious hepatitis, type A, B or C
- Patients under protection of a legal order.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1 ("2-cycles" trial)
The "2-cycles" trial will be available to patients who can be treated by radiation or intensive treatment (75 % of cases occurring in front line); they will then undergo 2 cycles of the lenalidomide-dexamethasone combination before radiation or intensive treatment (Group 1).
|
2 cycles of the lenalidomide-dexamethasone (Len-Dex) combination before radiation or intensive treatment
9 cycles of the Len-Dex combination
|
Experimental: Group 2 ( "9 cylces" Trial)
The "9-cycles" trial will be available to all other front-line patients (25 % of front-line patients) or patients in relapse or resistant, they will undergo 9 cycles of the lenalidomide-dexamethasone combination followed by maintenance therapy with lenalidomide alone for one year (Group 2).
|
2 cycles of the lenalidomide-dexamethasone (Len-Dex) combination before radiation or intensive treatment
9 cycles of the Len-Dex combination
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biological outcome
Time Frame: Two months for group 1
|
Decrease of monoclonal protein and serum VEGF level
|
Two months for group 1
|
Biological outcome
Time Frame: 2, 4 or 6 month for group 2
|
Decrease of monoclonal protein and serum VEGF level
|
2, 4 or 6 month for group 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical response
Time Frame: 2 months
|
Evaluation of the neurological (Overall Neuropathy Limitations Scale, Neuropsychological Impairment Scale and 10 m walking test) and other damages responses:
|
2 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Arnaud JACCARD, MD, Chu Limoges
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Immunoproliferative Disorders
- Disease
- Congenital Abnormalities
- Hematologic Diseases
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Paraproteinemias
- Blood Protein Disorders
- Abnormalities, Multiple
- Polyneuropathies
- Syndrome
- POEMS Syndrome
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protease Inhibitors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Dexamethasone
- Dexamethasone acetate
- BB 1101
- Lenalidomide
Other Study ID Numbers
- I10 015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on POEMS Syndrome
-
University of ArkansasJanssen Scientific Affairs, LLCRecruiting
-
Chiba UniversityCompleted
-
Peking Union Medical College HospitalCelgene CorporationCompleted
-
Istituto Clinico HumanitasUnknown
-
Mayo ClinicRecruitingPlasma Cell DisordersUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingPlasmacytoma | POEMS SyndromeUnited States
-
Asian Institute of Gastroenterology, IndiaRecruitingHemostatic Disorder | POEMS SyndromeIndia
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingVasculitis | Amyloidosis | Autoimmune Hemolytic Anemia | POEMS SyndromeChina
-
UNC Lineberger Comprehensive Cancer CenterRecruitingMultiple Myeloma | Amyloidosis | Smoldering Multiple Myeloma | Plasma Cell Leukemia | Cryoglobulinemia | Light Chain Deposition Disease | Castleman's Disease | Heavy Chain Deposition Disease | Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin ChangesUnited States
-
Rigshospitalet, DenmarkRecruitingPolyneuropathies | Diabetic Polyneuropathy | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | POEMS Syndrome | Multifocal Motor Neuropathy | Charcot-Marie-Tooth | hATTR Amyloidosis | Vasculitic Neuropathy | Idiopathic NeuropathyDenmark
Clinical Trials on Lenalidomide and dexamethasone
-
Universitätsklinikum Hamburg-EppendorfGemeinsamer Bundesausschuss (G-BA); Staburo GmbHRecruiting
-
Bristol-Myers SquibbCompletedMultiple MyelomaUnited States, France, Australia
-
Gesellschaft fur Medizinische Innovation - Hamatologie...ClinAssess GmbHCompletedMultiple MyelomaGermany
-
TJ Biopharma Co., Ltd.Active, not recruitingRefractory Multiple Myeloma | Multiple Myeloma in RelapseChina, Taiwan
-
University Health Network, TorontoCompletedMultiple Myeloma | Renal FailureCanada
-
University of LeedsTakeda; Cancer Research UK; CelgeneRecruitingMultiple MyelomaUnited Kingdom
-
European Myeloma NetworkSanofi; Amgen; EMN Research ItalyActive, not recruitingMultiple MyelomaCzechia, Germany, Greece, Italy, Netherlands, Norway, Spain
-
Celgene CorporationTerminatedDiffuse Large B-cell LymphomaUnited States, Canada, Australia
-
Samsung Medical CenterActive, not recruitingMultiple MyelomaKorea, Republic of
-
Hackensack Meridian HealthActive, not recruitingMultiple MyelomaUnited States